$ANAC Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Anacor Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Anacor Pharmaceuticals, Inc.. Get notifications about new insider transactions in Anacor Pharmaceuticals, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Option Exercise | A | 37.81 | 20,845 | 788,149 | 20,845 | |
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Grant | A | 0.00 | 5,020 | 0 | 29,087 | 24.1 K to 29.1 K (+20.86 %) |
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | Parker Geoffrey M. | Executive Vice Pres ... | Option Exercise | A | 0.00 | 6,930 | 0 | 6,930 | |
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | Parker Geoffrey M. | Executive Vice Pres ... | Option Exercise | A | 37.81 | 28,400 | 1,073,804 | 28,400 | |
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | Parker Geoffrey M. | Executive Vice Pres ... | Grant | A | 0.00 | 6,840 | 0 | 94,840 | 88 K to 94.8 K (+7.77 %) |
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | IPPOLITO VINCENT P | EVP & Chief Commerc ... | Option Exercise | A | 0.00 | 6,930 | 0 | 6,930 | |
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | IPPOLITO VINCENT P | EVP & Chief Commerc ... | Option Exercise | A | 37.81 | 28,400 | 1,073,804 | 28,400 | |
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | IPPOLITO VINCENT P | EVP & Chief Commerc ... | Grant | A | 0.00 | 6,840 | 0 | 79,603 | 72.8 K to 79.6 K (+9.40 %) |
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | BERNS PAUL L | President and CEO | Option Exercise | A | 0.00 | 12,890 | 0 | 12,890 | |
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | BERNS PAUL L | President and CEO | Option Exercise | A | 37.81 | 84,100 | 3,179,821 | 84,100 | |
Feb 05 2015 | ANAC | Anacor Pharmaceuti ... | BERNS PAUL L | President and CEO | Grant | A | 0.00 | 20,260 | 0 | 346,260 | 326 K to 346.3 K (+6.21 %) |
Feb 04 2015 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 37.41 | 600 | 22,448 | 4,600 | 5.2 K to 4.6 K (-11.54 %) |
Feb 04 2015 | ANAC | Anacor Pharmaceuti ... | Plattner Jacob j | Senior VP, Research | Sell | S | 37.35 | 6,875 | 256,781 | 51,475 | 58.4 K to 51.5 K (-11.78 %) |
Jan 06 2015 | ANAC | Anacor Pharmaceuti ... | Plattner Jacob j | Senior VP, Research | Sell | S | 32.09 | 6,875 | 220,619 | 58,350 | 65.2 K to 58.4 K (-10.54 %) |
Jan 06 2015 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 31.96 | 600 | 19,174 | 4,200 | 4.8 K to 4.2 K (-12.50 %) |
Dec 31 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Option Exercise | M | 7.25 | 2,708 | 19,633 | 5,291 | |
Dec 31 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Option Exercise | M | 7.25 | 8,333 | 60,414 | 7,666 | |
Dec 31 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Option Exercise | M | 5.00 | 3,250 | 16,250 | 3,849 | |
Dec 31 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Buy | M | 7.25 | 2,708 | 19,633 | 21,291 | 18.6 K to 21.3 K (+14.57 %) |
Dec 31 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Buy | M | 7.25 | 8,333 | 60,414 | 18,583 | 10.3 K to 18.6 K (+81.30 %) |
Dec 31 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Buy | M | 5.00 | 3,250 | 16,250 | 10,250 | 7 K to 10.3 K (+46.43 %) |
Dec 29 2014 | ANAC | Anacor Pharmaceuti ... | BERNS PAUL L | President and CEO | Sell | S | 30.82 | 25,000 | 770,505 | 325,000 | 350 K to 325 K (-7.14 %) |
Dec 29 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Gift | G | 0.00 | 28,000 | 0 | 0 | 28 K to 0 (-100.00 %) |
Dec 22 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Option Exercise | M | 5.59 | 12,062 | 67,427 | 14,938 | |
Dec 22 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Option Exercise | M | 6.92 | 7,011 | 48,516 | 18,489 | |
Dec 22 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Buy | M | 5.59 | 12,062 | 67,427 | 23,068 | 11 K to 23.1 K (+109.59 %) |
Dec 22 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Buy | M | 6.92 | 7,011 | 48,516 | 11,006 | 4 K to 11 K (+175.49 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | M | 5.54 | 3,000 | 16,620 | 0 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | M | 17.14 | 687 | 11,775 | 813 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | M | 7.55 | 1,500 | 11,325 | 0 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | M | 6.92 | 30,000 | 207,600 | 0 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | M | 6.74 | 15,000 | 101,100 | 0 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | M | 14.22 | 7,500 | 106,650 | 7,500 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | M | 5.20 | 12,500 | 65,000 | 0 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | M | 5.11 | 15,000 | 76,650 | 0 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | M | 0.60 | 834 | 500 | 0 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | M | 7.25 | 3,000 | 21,750 | 0 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 34.48 | 5,447 | 187,813 | 0 | 5.4 K to 0 (-100.00 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 34.45 | 44,384 | 1,528,873 | 28,000 | 72.4 K to 28 K (-61.32 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 34.92 | 120,032 | 4,191,878 | 72,384 | 192.4 K to 72.4 K (-62.38 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 34.91 | 30,801 | 1,075,183 | 5,447 | 36.2 K to 5.4 K (-84.97 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 35.79 | 3,000 | 107,359 | 36,248 | 39.2 K to 36.2 K (-7.64 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Buy | M | 5.54 | 3,000 | 16,620 | 39,248 | 36.2 K to 39.2 K (+8.28 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 35.79 | 687 | 24,585 | 36,248 | 36.9 K to 36.2 K (-1.86 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Buy | M | 17.14 | 687 | 11,775 | 36,935 | 36.2 K to 36.9 K (+1.90 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 35.79 | 1,500 | 53,680 | 36,248 | 37.7 K to 36.2 K (-3.97 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Buy | M | 7.55 | 1,500 | 11,325 | 37,748 | 36.2 K to 37.7 K (+4.14 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 35.79 | 30,000 | 1,073,592 | 36,248 | 66.2 K to 36.2 K (-45.28 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Buy | M | 6.92 | 30,000 | 207,600 | 66,248 | 36.2 K to 66.2 K (+82.76 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 35.79 | 15,000 | 536,796 | 36,248 | 51.2 K to 36.2 K (-29.27 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Buy | M | 6.74 | 15,000 | 101,100 | 51,248 | 36.2 K to 51.2 K (+41.38 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 35.79 | 7,500 | 268,398 | 36,248 | 43.7 K to 36.2 K (-17.14 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Buy | M | 14.22 | 7,500 | 106,650 | 43,748 | 36.2 K to 43.7 K (+20.69 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 35.79 | 12,500 | 447,330 | 36,248 | 48.7 K to 36.2 K (-25.64 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Buy | M | 5.20 | 12,500 | 65,000 | 48,748 | 36.2 K to 48.7 K (+34.48 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 35.79 | 15,000 | 536,796 | 36,248 | 51.2 K to 36.2 K (-29.27 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Buy | M | 5.11 | 15,000 | 76,650 | 51,248 | 36.2 K to 51.2 K (+41.38 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 35.79 | 834 | 29,846 | 36,248 | 37.1 K to 36.2 K (-2.25 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Buy | M | 0.60 | 834 | 500 | 37,082 | 36.2 K to 37.1 K (+2.30 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 35.79 | 3,000 | 107,359 | 36,248 | 39.2 K to 36.2 K (-7.64 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Buy | M | 7.25 | 3,000 | 21,750 | 39,248 | 36.2 K to 39.2 K (+8.28 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Option Exercise | M | 5.00 | 100 | 500 | 7,099 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Option Exercise | M | 5.00 | 4,800 | 24,000 | 7,199 | |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Sell | S | 36.00 | 100 | 3,600 | 7,000 | 7.1 K to 7 K (-1.41 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Buy | M | 5.00 | 100 | 500 | 7,100 | 7 K to 7.1 K (+1.43 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Sell | S | 36.09 | 4,800 | 173,251 | 7,000 | 11.8 K to 7 K (-40.68 %) |
Dec 12 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Buy | M | 5.00 | 4,800 | 24,000 | 11,800 | 7 K to 11.8 K (+68.57 %) |
Dec 10 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Option Exercise | M | 5.59 | 40,104 | 224,181 | 14,896 | |
Dec 10 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Option Exercise | M | 6.92 | 19,896 | 137,680 | 18,208 | |
Dec 10 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 36.52 | 40,104 | 1,464,734 | 4,800 | 44.9 K to 4.8 K (-89.31 %) |
Dec 10 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Buy | M | 5.59 | 40,104 | 224,181 | 44,904 | 4.8 K to 44.9 K (+835.50 %) |
Dec 10 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 36.52 | 19,896 | 726,670 | 4,800 | 24.7 K to 4.8 K (-80.56 %) |
Dec 10 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Buy | M | 6.92 | 19,896 | 137,680 | 24,696 | 4.8 K to 24.7 K (+414.50 %) |
Dec 03 2014 | ANAC | Anacor Pharmaceuti ... | Plattner Jacob j | Senior VP, Research | Sell | S | 34.08 | 900 | 30,672 | 65,225 | 66.1 K to 65.2 K (-1.36 %) |
Dec 03 2014 | ANAC | Anacor Pharmaceuti ... | Plattner Jacob j | Senior VP, Research | Sell | S | 33.23 | 5,975 | 198,565 | 66,125 | 72.1 K to 66.1 K (-8.29 %) |
Dec 03 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 34.03 | 100 | 3,403 | 4,800 | 4.9 K to 4.8 K (-2.04 %) |
Dec 03 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 33.25 | 500 | 16,623 | 4,900 | 5.4 K to 4.9 K (-9.26 %) |
Dec 01 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Option Exercise | M | 7.25 | 5,000 | 36,250 | 4,952 | |
Dec 01 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Sell | S | 35.00 | 5,000 | 175,000 | 3,995 | 9 K to 4 K (-55.59 %) |
Dec 01 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Buy | M | 7.25 | 5,000 | 36,250 | 8,995 | 4 K to 9 K (+125.16 %) |
Nov 04 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 29.10 | 600 | 17,457 | 5,400 | 6 K to 5.4 K (-10.00 %) |
Nov 04 2014 | ANAC | Anacor Pharmaceuti ... | Plattner Jacob j | Senior VP, Research | Sell | S | 29.32 | 6,875 | 201,563 | 72,100 | 79 K to 72.1 K (-8.71 %) |
Oct 02 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 23.85 | 600 | 14,312 | 6,000 | 6.6 K to 6 K (-9.09 %) |
Oct 02 2014 | ANAC | Anacor Pharmaceuti ... | Plattner Jacob j | Senior VP, Research | Sell | S | 24.47 | 6,875 | 168,231 | 78,975 | 85.9 K to 79 K (-8.01 %) |
Sep 30 2014 | ANAC | Anacor Pharmaceuti ... | Hove Anders D | Director | Sell | S | 25.00 | 20,000 | 500,000 | 2,725,535 | 2.7 M to 2.7 M (-0.73 %) |
Sep 22 2014 | ANAC | Anacor Pharmaceuti ... | Hove Anders D | Director | Sell | S | 24.87 | 738,500 | 18,366,495 | 2,745,535 | 3.5 M to 2.7 M (-21.20 %) |
Sep 22 2014 | ANAC | Anacor Pharmaceuti ... | Hove Anders D | Director | Sell | S | 24.87 | 1,500 | 37,305 | 3,484,035 | 3.5 M to 3.5 M (-0.04 %) |
Sep 16 2014 | ANAC | Anacor Pharmaceuti ... | Hove Anders D | Director | Sell | S | 24.99 | 75,000 | 1,874,250 | 3,485,535 | 3.6 M to 3.5 M (-2.11 %) |
Sep 16 2014 | ANAC | Anacor Pharmaceuti ... | Hove Anders D | Director | Sell | S | 24.98 | 15,000 | 374,700 | 3,560,535 | 3.6 M to 3.6 M (-0.42 %) |
Sep 12 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Option Exercise | M | 5.00 | 4,953 | 24,765 | 0 | |
Sep 12 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Option Exercise | M | 7.25 | 5,047 | 36,591 | 9,952 | |
Sep 12 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Sell | S | 24.25 | 4,953 | 120,110 | 3,995 | 8.9 K to 4 K (-55.35 %) |
Sep 12 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Buy | M | 5.00 | 4,953 | 24,765 | 8,948 | 4 K to 8.9 K (+123.98 %) |
Sep 12 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Sell | S | 24.25 | 5,047 | 122,390 | 3,995 | 9 K to 4 K (-55.82 %) |
Sep 12 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Buy | M | 7.25 | 5,047 | 36,591 | 9,042 | 4 K to 9 K (+126.33 %) |
Sep 12 2014 | ANAC | Anacor Pharmaceuti ... | WIERENGA WENDALL | Director | Option Exercise | A | 25.48 | 27,000 | 687,960 | 27,000 | |
Sep 08 2014 | ANAC | Anacor Pharmaceuti ... | Parker Geoffrey M. | Executive Vice Pres ... | Buy | P | 22.05 | 1,229 | 27,095 | 170,000 | 168.8 K to 170 K (+0.73 %) |
Sep 08 2014 | ANAC | Anacor Pharmaceuti ... | Parker Geoffrey M. | Executive Vice Pres ... | Buy | P | 21.77 | 5,361 | 116,712 | 168,771 | 163.4 K to 168.8 K (+3.28 %) |
Sep 04 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Option Exercise | M | 7.25 | 22,325 | 161,856 | 8,654 | |
Sep 04 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Option Exercise | M | 5.00 | 9,860 | 49,300 | 0 | |
Sep 04 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 23.32 | 600 | 13,989 | 6,600 | 7.2 K to 6.6 K (-8.33 %) |
Sep 04 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 23.34 | 94 | 2,194 | 7,200 | 7.3 K to 7.2 K (-1.29 %) |
Sep 04 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 23.34 | 1,000 | 23,335 | 7,294 | 8.3 K to 7.3 K (-12.06 %) |
Sep 04 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 23.30 | 22,325 | 520,108 | 8,294 | 30.6 K to 8.3 K (-72.91 %) |
Sep 04 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Buy | M | 7.25 | 22,325 | 161,856 | 30,619 | 8.3 K to 30.6 K (+269.17 %) |
Sep 04 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 23.30 | 9,860 | 229,709 | 8,294 | 18.2 K to 8.3 K (-54.31 %) |
Sep 04 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Buy | M | 5.00 | 9,860 | 49,300 | 18,154 | 8.3 K to 18.2 K (+118.88 %) |
Sep 04 2014 | ANAC | Anacor Pharmaceuti ... | Plattner Jacob j | Senior VP, Research | Sell | S | 23.34 | 6,875 | 160,444 | 85,850 | 92.7 K to 85.9 K (-7.41 %) |
Aug 29 2014 | ANAC | Anacor Pharmaceuti ... | LESCHLY MARK | Director | Sell | S | 22.50 | 13,067 | 294,008 | 0 | 13.1 K to 0 (-100.00 %) |
Aug 15 2014 | ANAC | Anacor Pharmaceuti ... | Plattner Jacob j | Senior VP, Research | Sell | S | 20.00 | 6,875 | 137,500 | 92,725 | 99.6 K to 92.7 K (-6.90 %) |
Aug 15 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Option Exercise | M | 6.92 | 10,253 | 70,951 | 38,104 | |
Aug 15 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Option Exercise | M | 7.25 | 1,000 | 7,250 | 30,979 | |
Aug 15 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 19.96 | 3,592 | 71,687 | 8,294 | 11.9 K to 8.3 K (-30.22 %) |
Aug 15 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Buy | M | 6.92 | 10,253 | 70,951 | 11,886 | 1.6 K to 11.9 K (+627.86 %) |
Aug 15 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 19.96 | 367 | 7,324 | 1,633 | 2 K to 1.6 K (-18.35 %) |
Aug 15 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Buy | M | 7.25 | 1,000 | 7,250 | 2,000 | 1,000 to 2 K (+100.00 %) |
Jun 06 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 14.65 | 620 | 9,082 | 0 | 620 to 0 (-100.00 %) |
Jun 06 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 14.73 | 1,000 | 14,728 | 620 | 1.6 K to 620 (-61.73 %) |
Jun 02 2014 | ANAC | Anacor Pharmaceuti ... | Hove Anders D | Director | Option Exercise | A | 14.22 | 15,000 | 213,300 | 15,000 | |
May 30 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | A | 14.22 | 15,000 | 213,300 | 15,000 | |
May 30 2014 | ANAC | Anacor Pharmaceuti ... | Parker Geoffrey M. | Executive Vice Pres ... | Option Exercise | A | 14.22 | 40,000 | 568,800 | 40,000 | |
May 30 2014 | ANAC | Anacor Pharmaceuti ... | RIEFLIN WILLIAM JL | Director | Option Exercise | A | 14.22 | 24,000 | 341,280 | 24,000 | |
May 30 2014 | ANAC | Anacor Pharmaceuti ... | LESCHLY MARK | Director | Option Exercise | A | 14.22 | 15,000 | 213,300 | 15,000 | |
May 30 2014 | ANAC | Anacor Pharmaceuti ... | KLINGENSTEIN PAUL H | Director | Option Exercise | A | 14.22 | 15,000 | 213,300 | 15,000 | |
May 30 2014 | ANAC | Anacor Pharmaceuti ... | Leonard Keith R | Director | Option Exercise | A | 14.22 | 27,000 | 383,940 | 27,000 | |
May 22 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 14.15 | 1,500 | 21,231 | 1,620 | 3.1 K to 1.6 K (-48.08 %) |
Apr 29 2014 | ANAC | Anacor Pharmaceuti ... | Sullivan Ryan T | Sr. VP and General ... | Option Exercise | A | 15.30 | 40,000 | 612,000 | 40,000 | |
Apr 29 2014 | ANAC | Anacor Pharmaceuti ... | Sullivan Ryan T | Sr. VP and General ... | Grant | A | 15.30 | 25,000 | 382,500 | 25,000 | 0 to 25 K |
Apr 22 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 15.60 | 1,500 | 23,397 | 3,120 | 4.6 K to 3.1 K (-32.47 %) |
Mar 25 2014 | ANAC | Anacor Pharmaceuti ... | BERNS PAUL L | President and CEO | Option Exercise | A | 21.21 | 100,000 | 2,121,000 | 100,000 | |
Mar 25 2014 | ANAC | Anacor Pharmaceuti ... | BERNS PAUL L | President and CEO | Option Exercise | A | 21.21 | 300,000 | 6,363,000 | 300,000 | |
Mar 25 2014 | ANAC | Anacor Pharmaceuti ... | BERNS PAUL L | President and CEO | Grant | A | 21.21 | 50,000 | 1,060,500 | 350,000 | 300 K to 350 K (+16.67 %) |
Mar 25 2014 | ANAC | Anacor Pharmaceuti ... | BERNS PAUL L | President and CEO | Grant | A | 21.21 | 300,000 | 6,363,000 | 300,000 | 0 to 300 K |
Mar 25 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Sell | S | 21.14 | 80,000 | 1,691,392 | 192,416 | 272.4 K to 192.4 K (-29.37 %) |
Mar 24 2014 | ANAC | Anacor Pharmaceuti ... | Parker Geoffrey M. | Senior Vice Preside ... | Buy | P | 20.11 | 5,000 | 100,533 | 163,410 | 158.4 K to 163.4 K (+3.16 %) |
Mar 24 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 22.77 | 619 | 14,095 | 4,620 | 5.2 K to 4.6 K (-11.82 %) |
Mar 24 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 22.29 | 2,381 | 53,069 | 5,239 | 7.6 K to 5.2 K (-31.25 %) |
Mar 19 2014 | ANAC | Anacor Pharmaceuti ... | Parker Geoffrey M. | Senior Vice Preside ... | Buy | P | 22.60 | 2,410 | 54,469 | 158,410 | 156 K to 158.4 K (+1.54 %) |
Mar 06 2014 | ANAC | Anacor Pharmaceuti ... | PERRY DAVID P | President and CEO | Sell | S | 20.24 | 7,500 | 151,814 | 361,306 | 368.8 K to 361.3 K (-2.03 %) |
Mar 06 2014 | ANAC | Anacor Pharmaceuti ... | PERRY DAVID P | President and CEO | Sell | S | 20.22 | 50,000 | 1,011,080 | 368,806 | 418.8 K to 368.8 K (-11.94 %) |
Mar 06 2014 | ANAC | Anacor Pharmaceuti ... | PERRY DAVID P | President and CEO | Sell | S | 20.20 | 7,500 | 151,503 | 418,806 | 426.3 K to 418.8 K (-1.76 %) |
Feb 21 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Sell | S | 19.33 | 3,000 | 57,977 | 7,620 | 10.6 K to 7.6 K (-28.25 %) |
Feb 21 2014 | ANAC | Anacor Pharmaceuti ... | Shapiro Lucy | Director | Option Exercise | A | 17.14 | 1,500 | 25,710 | 1,500 | |
Feb 10 2014 | ANAC | Anacor Pharmaceuti ... | Parker Geoffrey M. | Senior Vice Preside ... | Option Exercise | A | 17.14 | 54,000 | 925,560 | 54,000 | |
Feb 10 2014 | ANAC | Anacor Pharmaceuti ... | Maples Kirk R | SVP, Program Manage ... | Option Exercise | A | 17.14 | 47,000 | 805,580 | 47,000 | |
Feb 10 2014 | ANAC | Anacor Pharmaceuti ... | Zane Lee | SVP and Chief Medic ... | Option Exercise | A | 17.14 | 47,000 | 805,580 | 47,000 | |
Feb 10 2014 | ANAC | Anacor Pharmaceuti ... | Chanda Sanjay | SVP, Drug Developme ... | Option Exercise | A | 17.14 | 47,000 | 805,580 | 47,000 | |
Feb 10 2014 | ANAC | Anacor Pharmaceuti ... | PERRY DAVID P | President and CEO | Option Exercise | A | 17.14 | 165,000 | 2,828,100 | 165,000 | |
Feb 10 2014 | ANAC | Anacor Pharmaceuti ... | Plattner Jacob j | Senior VP, Research | Option Exercise | A | 17.14 | 47,000 | 805,580 | 47,000 | |
Feb 05 2014 | ANAC | Anacor Pharmaceuti ... | PERRY DAVID P | President and CEO | Sell | S | 16.71 | 7,500 | 125,303 | 426,306 | 433.8 K to 426.3 K (-1.73 %) |